Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001171843-25-005329
Filing Date
2025-08-12
Accepted
2025-08-12 16:09:15
Documents
15
Effectiveness Date
2025-08-12

Document Format Files

Seq Description Document Type Size
1 FORM S-8 s8_081125.htm S-8 52543
2 EXHIBIT 5.1 exh_51.htm EX-5.1 9874
3 EXHIBIT 23.1 exh_231.htm EX-23.1 3031
4 EX-FILING FEES exh_107.htm   iXBRL EX-FILING FEES 18436
5 GRAPHIC gibsondunn.jpg GRAPHIC 3840
  Complete submission text file 0001171843-25-005329.txt   208907

Data Files

Seq Description Document Type Size
17 EXTRACTED XBRL INSTANCE DOCUMENT exh_107_htm.xml XML 4759
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-289527 | Film No.: 251206734
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)